
Opinion|Videos|January 17, 2025
CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy
Panelists discuss how CAR T-cell therapy involves engineering a patient’s T cells to target cancer cells. The process includes cell collection, genetic modification, expansion, and reinfusion and streamlines the process with integrated workflows. Bridging therapy is provided in-house to treat patients awaiting CAR-T infusion.
Advertisement
Video content above is prompted by the following:
- Could you explain how CAR T-cell therapy works and describe the treatment process?
- Do you consider CAR T-cell therapy a complex process at your institution, or have you been able to streamline the logistics and integration into clinical workflows?
- Can you explain your institution’s approach to bridging therapy for patients awaiting CAR T-cell manufacturing and infusion?
- Do you send patients back to the community center or does it happen in-house?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
The Essential Role of Clinical Social Work in Oncology
2
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
3
Antiemetic Regimen Limits Chemo-Induced Nausea/Vomiting in Multiple Myeloma
4
Intravesical Mitomycin Produces Enduring Efficacy Across NMIBC Trials
5